



HAL
open science

Factors Associated With COVID-19 Hospitalizations and Deaths in French Nursing Homes

Anne-Laure Couderc, Florian Correard, Zeinab Hamidou, Emilie Nouguerede,
Robin Arcani, Joris Weiland, Anais Courcier, Pierre Caunes, Priscilla
Clot-Faybesse, Patrick Gil, et al.

► **To cite this version:**

Anne-Laure Couderc, Florian Correard, Zeinab Hamidou, Emilie Nouguerede, Robin Arcani, et al. Factors Associated With COVID-19 Hospitalizations and Deaths in French Nursing Homes. Journal of the American Medical Directors Association, 2021, 22 (8), pp.1581-1587.e3. 10.1016/j.jamda.2021.06.023 . hal-03585207

HAL Id: hal-03585207

<https://hal.science/hal-03585207v1>

Submitted on 2 Aug 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Factors associated with COVID-19 hospitalizations and deaths in French nursing homes

Running title: COVID-19 in nursing homes

Anne-Laure Couderc^{1*}, MD, Florian Correard^{2*}, PharmD, PhD, Zeinab Hamidou³, PhD, Emilie Nouguerede¹, PhD, Robin Arcani¹, MD, Joris Weiland¹, MD, Anais Courcier¹, MD, Pierre Caunes¹, MD, Priscilla Clot-Faybesse⁴, MD, Patrick Gil⁵, MD, Charlotte Berard², PharmD, Charlène Miola¹, MD, Julie Berbis³, MD PhD, Patrick Villani^{1*}, MD, PhD, Aurélie Daumas^{1*} MD PhD.

*Contributed equally to the work

Author Affiliations:

¹ Aix-Marseille Univ., Internal Medicine, Geriatrics and Therapeutic Department, Timone and Sainte Marguerite Hospital, AP-HM, Marseille, France

² Aix-Marseille Univ., Pharmaceutical Expertise And Clinical Research Unit, Pharmacy Department, Timone Hospital, AP-HM, Marseille, France

³ Aix-Marseille Univ, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS Health Service Research and Quality of Life Center, Marseille, France

⁴ Korian nursing homes group, Marseille, France,

⁵ MEDEOS nursing homes, Marseille, France

Corresponding Author:

Aurélie Daumas MD, PhD (aurelie.daumas@ap-hm.fr)

Internal Medicine, Geriatrics and Therapeutic Department, Timone and Sainte Marguerite Hospital, AP-HM, Marseille, France.

Phone: 33 4.91.38.87.19 Fax: 33 4.91.38.87.17

Keywords: SARS-Cov-2; nursing home; older residents; mortality; outcomes

Brief summary:

Male gender, diabetes, an altered level of consciousness, and dyspnea were all associated with a greater risk of hospitalization. Male gender, thermal dysregulation, and being aged >85 years old were all associated with increased mortality risk.

Abstract: 299 words**Main text: 3384 words****References: 40****Tables/figures: 4****Acknowledgments:**

The authors would like to thank the residents, healthcare workers and administrators in the participating nursing homes for their involvement. It was a true privilege for our hospital to collaborate with them. We especially thank Mrs. Sassoletti, Mrs. Amani, the coordinating physicians (Dr. Roux, Dr. Labarière, Dr. Peyrouse, Dr. Rambaud, Dr. Dilinger, Dr. Beaudet, Dr. Adevah, Dr. San José, Dr. Vidal, Dr. Amar, Dr. Bru and Dr. Midejean) and Dr. Herin from the Cerballiance Laboratory for making our work easier. Our thanks also to Pr. S. Honoré for his support.

Declaration of Sources of Funding: None**Author contributions:**

Couderc, Correard and Daumas had full access to all of the data in the study, and take responsibility for the integrity of the data and the accuracy of the data analysis. Couderc and Correard are joint first authors; Villani and Daumas are joint last authors.

Study concept and design: Couderc, Correard, Villani and Daumas

Data acquisition: All authors

Data analysis and interpretation: Couderc, Correard, Zeinab, Berbis and Daumas

Drafting of the manuscript: Couderc, Correard, Berbis, Villani and Daumas

Availability of data and materials:

The data are available from the corresponding author upon reasonable request.

Declaration of conflicts of interest: ALC reports personal fees from BMS, Ferring and Nutricia outside the submitted work. FC reports personal fees from Novartis, BMS, AstraZeneca and Pierre Fabre outside the submitted work. All authors declare no competing interests.

1 **Abstract**

2 **Objectives:** To describe the clinical characteristics and management of residents in French
3 nursing homes with suspected or confirmed coronavirus disease 2019 (COVID-19), and to
4 determine the risk factors for COVID-19-related hospitalization and death in this population.

5 **Design:** A retrospective multicenter cohort study

6 **Setting and Participants:** Four hundred and eighty nursing home residents with suspected or
7 confirmed COVID-19 between 1 March and 20 May 2020 were enrolled and followed until 2
8 June 2020 in 15 nursing homes in Marseille's greater metropolitan area.

9 **Methods:** Demographic, clinical, laboratory, treatment type, and clinical outcome data were
10 collected from patients' medical records. Multivariable analyses were used to determine
11 factors associated with COVID-19-related hospitalization and death. For the former, the
12 competing risk analysis - based on Fine and Gray's model - took death into account.

13 **Results:** 480 residents were included. Median age was 88 years (IQR 80-93), and 330
14 residents were women. A total of 371 residents were symptomatic (77.3%), the most common
15 symptoms being asthenia (47.9%), fever or hypothermia (48.1%), and dyspnea (35.6%). One
16 hundred and twenty-three patients (25.6%) were hospitalized and 96 (20%) died. Male gender
17 (sHR 1.63, 95% CI 1.12-2.35), diabetes (sHR 1.69, 95% CI 1.15-2.50), an altered level of
18 consciousness (sHR 2.36, 95% CI 1.40-3.98), and dyspnea (sHR 1.69, 95% CI 1.09-2.62)
19 were all associated with a greater risk of COVID-19-related hospitalization. Male gender (OR
20 6.63, 95% CI 1.04-42.39), thermal dysregulation (OR 2.64, 95% CI 1.60-4.38), falls (2.21
21 95% CI 1.02-4.75), and being aged >85 years old (OR 2.36 95% CI 1.32-4.24) were all
22 associated with increased COVID-19-related mortality risk, whereas polymedication (OR
23 0.46, 95% CI 0.27-0.77) and preventive anticoagulation (OR 0.46, 95% CI 0.27-0.79) were
24 protective prognostic factors.

25 **Conclusions and Implications:** Male gender, being aged >85 years old, diabetes, dyspnea,
26 thermal dysregulation, an altered level of consciousness, and falls, must all be considered
27 when identifying and protecting nursing home residents who are at greatest risk of COVID-
28 19-related hospitalization and death.

29

30 INTRODUCTION

31 Since December 2019, the number of older, frailer patients infected with severe acute
32 respiratory syndrome coronavirus 2 (SARS-CoV-2) has dramatically increased worldwide.
33 Infection rates are higher in the elderly than in younger populations, and health outcomes are
34 poorer.^{1,2} The literature on novel coronavirus disease 2019 (COVID-19) - which is caused by
35 SARS-CoV-2 - indicates that older adults are at particular risk of developing severe forms of
36 the disease^{3,4}, particularly those with pre-existing comorbidities⁵ and those who are frail (the
37 result of cognitive⁶ and functional⁷ impairment). Early reports also suggested that older
38 people may initially present more atypical COVID-19-related clinical manifestations and
39 biological results than younger adults.^{8,9}

40 In the context of the prevalence of COVID-19 in nursing home (NH) residents, research on
41 clinical characteristics, care management, and disease-related outcomes is still scarce. A study
42 in King county, Washington state, USA, reported that 54.5% of 101 NH residents infected
43 over a period of three weeks were hospitalized for COVID-19, and that 33.7% subsequently
44 died.¹⁰ In a multicenter study in NH in Maryland, USA, residents with multiple symptoms had
45 the highest risk of mortality and hospitalization. Interestingly, asymptomatic COVID-19 was
46 also associated with higher mortality risk in that study (20.6%).¹¹ In France, between 1 March
47 and 31 May 2020, of the 28 771 people who died from COVID-19, more than a third (10 327
48 persons) were living in nursing homes.¹² International comparisons of data are difficult
49 because of intra- and inter-country differences in NH in terms of organization, COVID-19
50 testing policies, therapeutic management, and approaches to quantifying COVID-19-related
51 deaths.¹³ However, the general observation in NH literature is that COVID-19 increased
52 mortality in NH residents in 2020.¹³⁻¹⁵ Given the relatively small number of related studies to
53 date, more research is needed on the clinical presentation and on risk factors for COVID-19-
54 related hospitalization and death in this population. Accordingly, we implemented a

55 multicenter retrospective study to describe the clinical characteristics, biological
56 characteristics, and healthcare management of a relatively large cohort of residents with
57 suspected or confirmed COVID-19 living in NH located in the greater metropolitan area of
58 Marseille. The secondary objectives were to determine the factors associated with COVID-
59 19-related hospitalization and with death.

60

61 **METHODS**

62

63 *Study design and participants*

64 We invited all 39 nursing homes located in the greater metropolitan area of Marseille to
65 participate in a 13-week retrospective observational cohort study. Of the 20 that agreed to
66 participate, 15 had at least one resident with suspected or confirmed COVID-19 at the time of
67 the study. The remaining five NH were therefore secondarily excluded. All residents with
68 suspected or confirmed COVID 19 between 1 March and 20 May 2020 were included. No
69 patient or patient legal representative opposed the use of their medical data when asked.

70 A suspected case was defined as a patient with acute respiratory illness who had been in
71 contact with a confirmed COVID-19 case in the 14 days prior to the onset of symptoms. A
72 confirmed case was defined as a suspected case who had tested positive for SARS-CoV-2
73 nucleic acid using a real-time reverse transcriptase-polymerase chain reaction (RT-PCR)
74 assay (nasal swabs). From the moment a first case was diagnosed in any given NH, screening
75 was performed for all residents approximately every 15 days. We monitored clinical
76 outcomes, including COVID-19-related hospitalization and death, until 2 June 2020, which
77 was the study end date. This end date was chosen as lockdown relaxation rules were
78 introduced facilitating greater NH access to relatives of residents.

79

80 With regard to investigating risk factors for hospitalization, residents who had the possibility
81 to be hospitalized from 21 March 2020 onwards – the date when French Public Health
82 Authorities facilitated hospital admissions for the country’s NH residents - were included in
83 the analysis. Prior to that date, only NH residents with few functional/cognitive impairments
84 and no severe comorbidity who presented severe clinical symptoms could be hospitalized in
85 France. With regard to investigating risk factors for death, all included residents (i.e., with
86 suspected or confirmed COVID 19) for the enrollment period (i.e., 1 March and 20 May
87 2020) were included.

88 The study was authorized by The National Institute for Health Data (number INDS- MR
89 3109280520) and was conducted in accordance with the MR-004 study-type reference
90 methodology approved by the National Commission for Information Technology and Civil
91 Liberties (CNIL). In accordance with French legislation, formal approval from an ethics
92 committee was not required for this type of retrospective non-interventional study based on
93 the use of previously recorded data.

94

95 *Data collection*

96 Trained physicians (ALC, AD) used a standardized electronic form to collect COVID-19-
97 specific data from clinical charts, laboratory findings, and chest computerized tomography
98 (CT) scans, as well as data from NH records and treatments both for COVID-19 and for pre-
99 existing comorbidities. They also collected the following data for each patient: demographic
100 information (age, gender, body mass index (BMI), most recent iso-resource dependence group
101 classification ¹⁶), comorbidities, and flu and pneumococcus vaccination status.

102 To define their level of dependency, elderly people in France are divided into one of six iso-
103 resource groups, which reflect different stages of loss of autonomy.¹⁶ NH residents classified
104 into iso-resource groups 1, 2 or 3 must be assisted in most or all their daily activities. We

105 defined cognitive impairment as a score of < 24 according to Mini-Mental State
106 Examination¹⁷ (MMSE) test, or the presence of cognitive impairment symptoms (wandering,
107 hallucinations, hostility/aggressiveness or history of cognitive disorder). Undernutrition and
108 obesity were defined as a BMI of < 21 and ≥ 30 , respectively.

109 The date of disease onset was defined as the day when COVID-19 symptoms were first
110 noticed or, for asymptomatic patients, the day a patient had a positive RT-PCR test. The
111 trained physicians collected data for the following symptoms suggestive of COVID-19 from
112 the patients' medical records: general symptoms (sudden deterioration in general health
113 condition or asthenia, anorexia, fever or hypothermia (thermal dysregulation), headaches,
114 myalgia and/or arthralgia), respiratory symptoms, ear nose and throat (ENT) symptoms,
115 gastrointestinal symptoms, worsening depression and geriatric-related syndromes (falls,
116 delirium (acute confusional state), and altered level of consciousness (defined as a Glasgow
117 coma score < 14)). Data on routine blood tests (blood count, renal and liver function, C-
118 reactive protein, creatine phosphokinase and D-dimers) and on chest CT scan results were
119 also collected. For all included patients, data on medications for pre-existing chronic
120 pathologies, polymedication (≥ 5 usual drugs per day), and management of COVID-19 were
121 also recorded. Some patients were 'home hospitalized', that is to say they were provided some
122 elements of hospital-type care for COVID-19 in their NH by an authorized external (i.e., not
123 NH-based) team of specialists. These elements included hydroxychloroquine treatment,
124 perfusions for hydration, and end-of-life care. Home hospitalization did not exclude potential
125 subsequent normal hospitalization if symptoms deteriorated. The numbers of home
126 hospitalized, hospitalized, and deceased patients were recorded. The reasons for home
127 hospitalization (which reflected the availability of each of the three hospital-type care
128 elements listed above), the reasons for hospitalization, and the causes of death were all

129 collected, as were symptom duration, time between disease onset and hospital admission, and
130 the time between disease onset and death.

131

132 *Statistical analysis*

133 As the study focused on all suspected or confirmed COVID-19 NH residents specifically
134 during the enrolment period, no a priori power calculation was needed. Continuous variables
135 were presented as the median and interquartile range (IQR) with 95% confidence intervals
136 (CI). Categorical variables were expressed as the number of patients (percentage) with 95%
137 CI.

138 Our analysis aimed to explore the association between epidemiological/clinical characteristics
139 and the risk of hospitalization/death in COVID-19 infected NH residents. Univariate and
140 multivariate logistic regression models were used to analyze all the variables studied as
141 potential factors of hospitalization/death (odds ratio; OR). Competing risk analysis based on
142 Fine and Gray's model was used to measure the time from disease onset to hospitalization, in
143 order to take into account the fact that patients who died could not have been hospitalized
144 after their death. Cox proportional hazard regression models were used to estimate cause-
145 specific hazard ratios (sHRs). The follow-up time was defined as the time between the date of
146 disease onset and the date of hospitalization.

147 All variables with a p -value of less than 0.05 in the univariate logistic regression or Cox
148 regression models were included in the multivariable analyses. Given the large number of
149 variables with $p < 0.05$, we decided to select only those which were most clinically relevant
150 and which had few missing data for the multivariable analysis, in order to respect the
151 maximum authorized number of variables in each model (10 and 9 for the hospitalization and
152 death models, respectively)¹⁸. For correlated variables, the variable selected was the greatest
153 clinical relevance.

154 All statistical analyses were conducted using SPSS software. A p-value < 0.05 was chosen for
155 the statistical significance threshold.

156

157 **RESULTS**

158

159 *Patients' demographic and clinical characteristics (Table 1)*

160 Between 1 March and 20 May 2020, of the 1392 residents in the 15 participating nursing
161 homes in the greater metropolitan area of Marseille, a total of 480 (34.5%) had suspected or
162 confirmed COVID-19 and were included in the present study.

163

164 Median age of the study sample was 88 years (IQR 80-93, range 65-105), and 330 patients
165 (68.8%) were women. All patients had at least one comorbidity. Neurocognitive disorders
166 were the most common comorbidity, affecting 406 (84.6%) patients, followed by
167 hypertension (257, 53.5%), and depression (216, 45.0%). Eighty-six patients (17.9%) had
168 diabetes and 51 (10.6%) had chronic pulmonary disease. With regard to weight status, 186
169 (38.8%) were undernourished, and 43 (9.0%) were obese. The majority of residents (408,
170 85.0%) were classified in iso-resource groups 1, 2, or 3.

171 Of the 480 patients included, 371 (77.3%) were symptomatic, the most common symptoms
172 being thermal dysregulation (48.1%) and asthenia (47.9%), followed by dyspnea (35.6%), dry
173 cough (27.7%), and anorexia (21.0%). Gastrointestinal symptoms and delirium were observed
174 in 17.7 and 12.3% of the patients, respectively. ENT symptoms, falls and an altered level of
175 consciousness were uncommon. The median duration of symptoms was 17.0 days (IQR 8.0-
176 28.5; N=110). ~~Of the 480 patients, 370 had incomplete clinical data.~~

177

178 *Laboratory and imaging findings following COVID-19 diagnosis*

179 Table 1 shows the biological characteristics of 339 patients with many missing laboratory
180 data. One hundred and forty-one patients (29.4%) did not have a blood test at diagnosis of
181 infection.

182 Lymphopenia, neutropenia and thrombocytopenia occurred in 109 (32.2%), 23 (6.8%) and 40
183 (11.8%) patients, respectively. The median C-reactive protein was 26 mg/L (IQR 7-67).
184 Of the 461 patients (96.0%) who had an RT-PCR test, 446 (92.9%) tested positive for
185 COVID-19. Only 42 patients had chest CT scans during hospitalization. All the scans showed
186 anomalies supporting the diagnosis of COVID-19.

187

188 *Treatments and clinical outcomes*

189 The median number of medications for pre-existing chronic illnesses was 7 (IQR 4-9.2).
190 Polymedication was present for 348 patients (72.5%).

191 With regard to treatment for suspected or confirmed COVID-19, 375 patients (78.1%)
192 received azithromycin. Of these, 117 (24.4%) also received hydroxychloroquine, and 346
193 (72.1%) a second antibiotic (penicillin (7.9%) or ceftriaxone (59.4%)). No patient received
194 antivirals or anti-inflammatory agents. Preventive anticoagulation was initiated in 203 patients
195 (42.3%). Moreover, 163 patients (34.0%) received oxygen therapy, while 220 (45.8%)
196 received intravenous or subcutaneous hydration.

197

198 One hundred and thirty-four residents (27.9%) were home hospitalized (Supplementary Table
199 A1). The reasons for home hospitalization were to offer hydroxychloroquine treatment
200 (79.9%), perfusion for hydration (11.2%) and end-of-life care (6.0%), provided by an external
201 team of specialists in the 15 participating NH.

202 Between 21 March and 20 May 2020, of the 463 (26.6%) patients still alive, 123 were
203 hospitalized. Fifteen of the 134 residents who received home hospitalization were
204 subsequently admitted to a hospital during this same period. The main cause for
205 hospitalization was respiratory distress syndrome (45.5%). Median time from symptom onset
206 to hospitalization was 5.0 days (IQR 2.0-10.0).

207 Ninety-six residents (20%) died over the study period: 42 in hospital and 54 in NH; 57
208 (11.9%) received end-of-life care. Median time from symptom onset to death was 12.0 days
209 (IQR 8.0-24.3). Death was attributed to COVID-19 in most cases (90.5%).

210

211 *Factors associated with hospitalization and death*

212 Sixteen factors were associated with an increased risk of COVID-19-related hospitalization in
213 the univariate analysis (Table 2 and supplementary Table A2). In multivariable and competing
214 risk analyses, male gender (sHR 1.63, 95% CI 1.12-2.35; $p=0.010$), diabetes (sHR 1.69, 95%
215 CI 1.15-2.50; $p=0.008$), an altered level of consciousness (sHR 2.36, 95% CI 1.40-3.98;
216 $p=0.001$), and dyspnea (sHR 1.69, 95% CI 1.09-2.62; $p=0.018$) all remained associated with
217 an increased risk of hospitalization (Figure 1).

218 Twenty-two factors were associated with increased risk of mortality in univariate analysis
219 (Table 3 and see Supplementary Table A3). In the multivariable model, male gender (OR
220 6.63, 95% CI 1.04-42.39; $p=0.001$), thermal dysregulation (OR 2.64, 95% CI 1.60-4.38;
221 $p=0.0001$), falls (2.21 95% CI 1.02-4.75; $p=0.043$), and being aged >85 years old (OR 2.36
222 95% CI 1.32-4.24; $p=0.004$) were all independently associated with an increased risk of
223 mortality. Conversely, polymedication (OR 0.46, 95% CI 0.27-0.77) and preventive
224 anticoagulation (OR 0.46, 95% CI 0.27-0.79) were protective prognostic factors (Figure 1).

225

226

227 **DISCUSSION**

228 To our knowledge, this is the first multicenter study in France to describe a relatively large
229 cohort of older residents (mean age of 88 years) with suspected or confirmed COVID-19 in a
230 large number of nursing homes. Among the 480 residents included, 77.3% were symptomatic,
231 and 26.6% were hospitalized. Male gender, diabetes, an altered level of consciousness, and
232 dyspnea, were all associated with an increased risk of hospitalization. The overall mortality
233 was 20% during the study period. Being >85 years old, male gender, thermal dysregulation
234 and falls, were all associated with an increased risk of mortality.

235

236 In the literature, the number of deaths linked to COVID-19 in NH is unclear. In France, as of
237 1 June 2020, the mortality among NH residents with diagnosed COVID-19 was 27.4%.¹⁹
238 Sacco et al.¹⁴ also found a 27% COVID-19 mortality diagnosed residents in their study of a
239 middle-sized nursing home in Maine-et-Loire, in the west of France. In the USA, McMichael
240 et al. found a mortality percentage of 33.7% in 101 residents in an NH in Washington,¹⁰ while
241 more recently, Tang et al.¹¹ reported 20.6% COVID-19 mortality - which is closer to that in
242 our study- in 1970 residents in an NH in Maryland. With regard to hospitalization, 26.6% of
243 our study sample were admitted to hospital. In the literature, this percentage varies between
244 16 and 54.5%.^{10,11,14,20}

245

246 To our knowledge, our cohort is the oldest (in terms of patients' age) described in the
247 literature.^{7,8,11,21,22} Unsurprisingly, all studies have shown that older patients have a poorer
248 COVID-19 prognosis.^{1,8,23,24-27} Furthermore, the present study is one of the first to investigate
249 prognostic factors associated with the risk of hospitalization and death in NH residents.
250 Unlike other French and international studies^{10,14}, we did not consider staff members' or
251 visitors' infectious status.

252 With regard to the factors listed above which were associated with hospitalization and death,
253 different studies on COVID-19 have found that men are significantly more likely to get the
254 disease than women^{9,28}, and that male gender is significantly associated with COVID-19-
255 related mortality.^{8,21} Comorbidities including hypertension, diabetes, and
256 cardiovascular/respiratory diseases affect COVID-19 patient prognosis. In particular, diabetes
257 is associated with a higher risk of developing a severe form of the disease and admission to an
258 intensive care unit.^{29,30} In Tang et al.'s study in Maryland, renal disease, diabetes and
259 depression were associated with an increased risk of hospitalization.¹¹ In line with the
260 literature^{8,23,30}, older age and comorbidities were significantly associated with death in our
261 study. Falls are an atypical symptom of COVID-19^{14,31}, and our study is the first to show an
262 association between falls and hospitalization of NH residents with confirmed or suspected
263 COVID-19. Unlike the literature³², we found that polymedication was a protective factor
264 against death.

265

266 Most patients in our study sample were symptomatic, which reflects findings in the literature.
267 ^{8,21} Having said that, some studies have reported a substantial proportion of asymptomatic
268 patients.^{11,33} We may have overestimated the proportion of symptomatic patients because we
269 took into account symptomatic residents who tested negative for a RT-PCR test after being in
270 contact with a confirmed COVID-19 case. Furthermore, the fact that France conducted
271 systematic screening campaigns in NH, limited the number of asymptomatic people not
272 screened. The most common COVID-19 symptoms in our study sample were thermal
273 dysregulation and asthenia, followed by respiratory symptoms. These symptoms are
274 consistent with previously reports. Anorexia, a common digestive symptom of many illnesses
275 in older patients³⁴, was present in 21% of residents in our study. ENT symptoms were present
276 in less than 10% of the residents, which reflects findings in the literature that anosmia and

277 ageusia are more frequently found in young patients.^{5,35} Atypical presentation in older adults
278 may include gastrointestinal symptoms and geriatric syndromes complicating the diagnostic
279 pathway. Surprisingly, delirium was less frequent in our study than in previous studies on NH
280 adults^{7,36}, perhaps due to the fact that 84.6% of our study sample were diagnosed with
281 neurocognitive disorders and consequently, it may have been difficult to accurately attribute
282 symptoms to delirium or to underlying dementia.

283

284 With regard to COVID-19 management and treatment, 78.1% of our study sample received
285 azithromycin while 72.1% also received another antibiotic. Less than a quarter were
286 prescribed hydroxychloroquine. We found that azithromycin was independently associated
287 with a reduced risk of death in univariate analysis. However, larger studies have shown no
288 such benefit, and as of June 2020, this treatment was no longer recommended.^{37,38} We found
289 no association between hydroxychloroquine and hospitalization or mortality. Recent clinical
290 data documented no benefit in patients treated with hydroxychloroquine, whether alone or in
291 combination with azithromycin, and warned about potential adverse effects.^{37,39}

292 Almost half of our patients received preventive anticoagulation. It is very likely that many of
293 the others had previously had anticoagulation treatment. Preventive anticoagulation was
294 recommended because of frequent thromboembolic events in cases of COVID-19.⁴⁰
295 Preventive anticoagulation was associated in our multivariable analysis with a reduced risk of
296 death, which reflects previous findings.²²

297

298 Our study has limitations. First, despite its multicenter design, it only included residents in the
299 greater metropolitan area of one city - Marseille - and only from 15 out of 20 nursing homes
300 which agreed to participate (as the other five had no suspected or confirmed COVID-19 case).
301 Although relatively large, the size of the cohort might have prevented some specific clinical

302 symptoms from being highlighted and limited the identification of all prognostic factors.
303 Furthermore, because of its retrospective design, the study had missing data. The missing data
304 were primarily laboratory data, limiting the study's ability to draw conclusions about
305 laboratory-base predictors of outcomes. We selected only variables which were most relevant,
306 and which had few missing data for the multivariable analysis. In addition, only hospitalized
307 patients had chest CT scans. With regard to the investigation of risk factors of hospitalization,
308 we included only residents hospitalized from 21 March 2020 onwards (i.e., three weeks after
309 the study start date), as this was the date that French Public Health Authorities facilitated
310 hospitalization for NH residents throughout the country. Before this date, the advice given
311 was to provide residents with care in their NH (NH-staff based care, and, when possible,
312 home hospitalization), and to only transfer those with severe and critical forms of COVID-9
313 to hospital. Home hospitalization in NH continued even after 21 March 2020.
314 Finally, it is important to underline that our results reflect the specific French healthcare and
315 NH context regarding COVID-19 management, and cannot be extrapolated to other countries.

316

317 **Conclusions and Implications**

318 This is the largest retrospective multicenter cohort study of NH residents with suspected or
319 confirmed COVID-19 to date in France. Furthermore, our cohort is the oldest (in terms of
320 residents' age) in the literature. A minority of older residents had uncommon, atypical
321 symptoms of COVID-19. These were not associated with poor prognosis. Male gender,
322 diabetes, an altered level of consciousness, and dyspnea were all associated with an increased
323 risk of hospitalization in this frail population. Multivariable regression also showed that male
324 gender, thermal dysregulation, falls and being aged > 85 years old, were all associated with an
325 increased risk of death. Anticoagulation was a protective factor against death.

326 While dyspnea is a precursor to hospitalization, in NH residents, the risk of COVID-19-
327 related mortality was linked to demographic data and the occurrence of falls, and these factors

328 should be considered when caring for COVID-19-diagnosed NH residents in order to improve
329 prognosis.

330

331

332 **References:**

333

334 1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with
335 SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational
336 study. *Lancet Respir Med* 2020;8:475-481.
337

338 2. Aw D, Woodrow L, Ogliari G, et al. Association of frailty with mortality in older
339 inpatients with Covid-19: a cohort study. *Age Ageing* 2020;49:915-922.
340

341 3. Liu W, Tao Z-W, Wang L, et al. Analysis of factors associated with disease outcomes in
342 hospitalized patients with 2019 novel coronavirus disease. *Chin Med J* 2020;133:1032-
343 1038.
344

345 4. D'Adamo H, Yoshikawa T, Ouslander JG. Coronavirus Disease 2019 in Geriatrics and
346 Long-Term Care: The ABCDs of COVID-19. *J Am Geriatr Soc* 2020;68:912-917.
347

348 5. Borges do Nascimento IJ, Cacic N, Abdulazeem HM, et al. Novel Coronavirus Infection
349 (COVID-19) in Humans: A Scoping Review and Meta-Analysis. *J Clin Med* 2020;9.
350

351 6. Wang H, Li T, Barbarino P, et al. Dementia care during COVID-19. *Lancet* 2020;395:
352 1190-1191.
353

354 7. Zerah L, Baudouin É, Pépin M, et al. Clinical Characteristics and Outcomes of 821 Older
355 Patients with SARS-Cov-2 Infection Admitted to Acute Care Geriatric Wards. *J Gerontol*
356 *A Biol Sci Med Sci* 2020.
357

358 8. Chen T, Dai Z, Mo P, et al. Clinical characteristics and outcomes of older patients with
359 coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered,
360 retrospective study. *J Gerontol A Biol Sci Med Sci* 2020.
361

362 9. Lithander FE, Neumann S, Tenison E, et al. COVID-19 in older people: a rapid clinical
363 review. *Age Ageing* 2020;49:501-515.
364

365 10. McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a Long-Term
366 Care Facility in King County, Washington. *N Engl J Med* 2020;382:2005-2011.
367

- 368 11. Tang O, Bigelow BF, Sheikh F, et al. Outcomes of Nursing Home COVID-19 Patients by
369 Initial Symptoms and Comorbidity: Results of Universal Testing of 1970 Residents. *J Am*
370 *Med Dir Assoc* 2020.
371
- 372 12. Santé publique France. Coronavirus (COVID-19).
373 <https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19>. Accessed July 15,
374 2020.
375
- 376 13. Comas-Herrera A, Zalakaín J, Lemmon E, et al. Mortality associated with COVID-19
377 outbreaks in care homes: early international evidence. Article in LTCcovid.org,
378 International Long-Term Care Policy Network, CPEC-LSE, 1st February 2021.
379
- 380 14. Sacco G, Foucault G, Brière O, Annweiler C. COVID-19 in seniors: Findings and lessons
381 from mass screening in a nursing home. *Maturitas* 2020;141:46-52.
382
- 383 15. Hollinghurst J, Lyons J, Fry R, et al. The impact of COVID-19 on adjusted mortality risk
384 in care homes for older adults in Wales, UK: a retrospective population-based cohort
385 study for mortality in 2016-2020. *Age Ageing* 2020.
- 386 16. Costa N, Hoogendijk EO, Mounié M, Bourrel R, Rolland Y, Vellas B, et al. Additional
387 Cost Because of Pneumonia in Nursing Home Residents: Results From the Incidence of
388 Pneumonia and Related Consequences in Nursing Home Resident Study. *J Am Med Dir*
389 *Assoc* 2017;18:453.e7-453.e12.
- 390 17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for
391 grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;12:189-198.
- 392 18. Li G, Taljaard M, Van den Heuvel E, Levine M, Cook D, Wells G, et al. An introduction
393 to multiplicity issues in clinical trials: the what, why, when and how, *International*
394 *Journal of Epidemiology* 2017;46:746-755.
- 395 19. COVID-19 Point épidémiologique hebdomadaire du 4 juin 2020. 2020
396 <https://www.santepubliquefrance.fr/content/download/257630/2628879>. Accessed July
397 15, 2020.
398
- 399 20. Mc P, Lh C, S B, et al. Asymptomatic SARS-CoV-2 infection and COVID-19 mortality
400 during an outbreak investigation in a skilled nursing facility. *Clinical infectious diseases* :
401 an official publication of the Infectious Diseases Society of America 2020
402 <https://pubmed.ncbi.nlm.nih.gov/32548628>. Accessed December 10, 2020.
403
- 404 21. Annweiler C, Sacco G, Salles N, et al. On Behalf of the SFGG Covid-19 Study Group.
405 National French Survey of Symptoms in People Aged 70 and Over Diagnosed with
406 Covid-19. *Clin Infect Dis* 2020.
407
- 408 22. Bousquet G, Falgarone G, Deutsch D, et al. ADL-dependency, D-Dimers, LDH and
409 absence of anticoagulation are independently associated with one-month mortality in
410 older inpatients with Covid-19. *Aging (Albany NY)* 2020;12:11306-11313.
411

- 412 23. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
413 with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054-
414 1062.
415
- 416 24. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV
417 infected patients linked to viral loads and lung injury. *Sci China Life Sci* 2020;63:364-
418 374.
419
- 420 25. Chen R, Liang W, Jiang M, et al. Risk Factors of Fatal Outcome in Hospitalized Subjects
421 With Coronavirus Disease 2019 From a Nationwide Analysis in China. *Chest*
422 2020;158:97-105.
423
- 424 26. Guan W-J, Zhong N-S. Clinical Characteristics of Covid-19 in China. Reply. *N Engl J*
425 *Med* 2020;382:1861-1862.
426
- 427 27. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying
428 in Relation to COVID-19 in Italy. *JAMA* 2020.
429
- 430 28. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A
431 systematic literature review and meta-analysis. *J Infect* 2020.
432
- 433 29. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases
434 on COVID-19 in China. *Clin Res Cardiol* 2020;109:531-538.
435
- 436 30. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
437 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases
438 From the Chinese Center for Disease Control and Prevention. *JAMA* 2020;323:1239-
439 1242.
440
- 441 31. Gawronska K, Lorkowski J. Falls as One of the Atypical Presentations of COVID-19 in
442 Older Population. *Geriatr Orthop Surg Rehabil* 202;12:2151459321996619.
443
- 444 32. Corradini E, Ventura P, Ageno W, Cogliati CB, Muiesan ML, Girelli D, et al. Clinical
445 factors associated with death in 3044 COVID-19 patients managed in internal medicine
446 wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal
447 Medicine (SIMI). SIMI-COVID-19 Collaborators. *Intern Emerg Med*. 2021.
448
- 449 33. Blain H, Rolland Y, Tuailon E, et al. Efficacy of a Test-Retest Strategy in Residents and
450 Health Care Personnel of a Nursing Home Facing a COVID-19 Outbreak. *J Am Med Dir*
451 *Assoc* 2020;21:933-936.
452
- 453 34. Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal Manifestations of SARS-CoV-2
454 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic
455 Review and Meta-analysis. *Gastroenterology* 2020.
456

- 457 **35.** Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory
458 dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus
459 disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol* 2020.
460
- 461 **36.** Zazzara MB; Penfold RS, Roberts AL, et al. Probable delirium is a presenting symptom
462 of COVID-19 in frail, older adults: a cohort study of 322 hospitalised and 535
463 community-based older adults. *Age Ageing* 2020.
- 464 **37.** Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With
465 Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With
466 COVID-19 in New York State. *JAMA* 2020.
467
- 468 **38.** Sbidian E, Josse J, Lemaitre G, et al. Hydroxychloroquine with or without azithromycin
469 and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a
470 cohort study of 4,642 in-patients in France. *medRxiv* 2020; 2020.06.16.20132597.
471
- 472 **39.** Alvi MM, Sivasankaran S, Singh M. Pharmacological and non-pharmacological efforts at
473 prevention, mitigation, and treatment for COVID-19. *J Drug Target* 2020;1-46.
474
- 475 **40.** Wu T, Zhihong Z, Yang D, et al. Venous thromboembolic events in patients with
476 COVID-19: a systematic review and meta-analysis. *Age Ageing* 2020.
477
478

479 **Appendix 1**

480 **Table A1:** Characteristics of the 134 residents who benefited from ‘home hospitalization’

481 **Appendix 2**

482 **Table A2:** Variables not associated with an increased risk of hospitalization: univariate analysis of the
483 123/463 persons hospitalized

484 **Appendix 3**

485 **Table A3:** Variables not associated with an increased risk of hospitalization: univariate analysis of the
486 96/480 persons who died

487

488

489

490

491

492 **Figure 1:** Multivariable analysis of hospitalizations with competing risk (463 residents) and deaths
493 (480 residents)

494

495

496 **Table 1.** Characteristics of the study sample (n=480)

Characteristics	N or Median (IQR)	% or [min-max]	Missing data	Characteristics	N or Median (IQR)	% or [min-max]	Missing data
Age (years)	88 (80-93)	[65-105]	-	Symptoms	371	77.3	-
65-74	67	14.0		Dyspnea	171	35.6	-
75-84	112	23.3		Dry cough	133	27.7	-
85-94	213	44.4		Thermal dysregulation	231	48.1	-
95-105	88	18.3		Fever	217	45.2	-
Gender				Asthenia	230	47.9	-
Male	150	31.3	-	Anorexia	101	21.0	-
Female	330	68.8	-	Gastrointestinal symptoms	85	17.7	-
Nutrition* Undernutrition	186	38.8	-	Myalgia or arthralgia	14	2.9	-
Status Obesity	43	9.0	-	Headaches	8	1.7	-
Polymedication ≥5 drugs for pre-existing conditions	348	72.5	-	ENT symptoms	40	8.3	-
Vaccinated for Flu	379	79.0	-	Falls	39	8.1	-
Pneumococcus	188	39.2	-	Delirium	59	12.3	-
Comorbidities				Worsening depression	27	5.6	-
Cognitive impairment**	406	84.6	-	Altered level of consciousness	32	6.7	-
Hypertension	257	53.5	-	Positive RT-PCR test result	446	92.9	-
Dyslipidemia	31	6.5	-	Laboratory findings	339	70.6	-
Type 2 diabetes	86	17.9	-	Red blood cells (G/L) ¹	4 (4-5)	[2-6]	164
Cerebrovascular disease	95	19.8	-	White blood cells (G/L) ²	6 (4-7)	[2-20]	162
Coronaropathy	70	14.6	-	Neutrophils (G/L) ³	4 (3-5)	[1-21]	165
Congestive heart failure	71	14.8	1	Neutropenia****	23	6.8	165
Atrial fibrillation	91	19.0	-	Lymphocytes (G/L) ⁴	1 (1-2)	[0-7]	164
Asthma	11	2.3	-	Lymphopenia****	109	32.2	164
Chronic obstructive pulmonary disease	51	10.6	-	Thrombocytopenia****	40	11.8	443
Chronic respiratory insufficiency	16	3.3	-	AST (UI/L) ⁶	25 (20-36)	[11-147]	344
Depression	216	45.0	-	ALT (UI/L) ⁷	14 (10-21)	[5-68]	344
Psychiatric disorders	51	10.6	-	AP (UI/L) ⁸	76 (66-86)	[35-338]	410
Chronic kidney disease	69	14.4	-	GGT (UI/L) ⁹	27 (15-39)	[6-313]	353
Cancer history	31	6.5	-	Bilirubin (µmol/L) ¹⁰	6 (4-8)	[2-20]	413
Iso-resource groups			3	Creatinine (µmol/L) ¹¹	77 (64-107)	[64-107]	175
1	102	21.3		GFR (ml/min) ¹²	41.1 (29.8-57.5)	[5.2-174.4]	178
2	228	47.5		Potassium (mmol/L) ¹⁴	4 (4-4)	[2-7]	166
3	78	16.3		Sodium (mmol/L) ¹³	140 (138-143)	[125-173]	168
4	61	12.7		D dimer (µg/L) ¹⁵	911 (680-1476)	[215-32463]	381
5 and 6	8	1.7		CPK (UI/L) ¹⁶	74 (42.3-225.3)	[13-4036]	398
Hospitalization***							
In COVID-19 unit	123	26.6	-				
Home hospitalization	134	27.9	-				
End-of-life care	57	11.9	-				
Death							
In COVID-19 unit	42	8.5	-				

In nursing home	54	11.3	CRP (mg/L) ⁵	26 (7-67)	[0-350]	169
497						
498						
499						
500						
501						
502						
503						
504						
505						
506						
507						
508						
509						
510						
511						
512						
513						
514						
515						
516						
517						
518						
519						
520						
521						
522						
523						
524						
525						
526						
527						
528						
529						
530						
531						
532						
533						
534						
535						
536						
537						
538						
539						
540						
541						
542						
543						
544						
545						
546						

¹ (normal range: 4.4-5.7), ² (normal range: 3.9-10.9), ³ (normal range: 1.7-7.1), ⁴ (normal range: 1.1-3.2), ⁵ (normal range: 0-10), ⁶ (normal range: 0-50), ⁷ (normal range: 0-50), ⁸ (normal range: 35-130), ⁹ (normal range: 0-60), ¹⁰ (normal range: 0-21), ¹¹ (normal range: 60-104), ¹² (normal range: >60), ¹³ (normal range: 136-145), ¹⁴ (normal range : 3.4-4.5), ¹⁵ (normal range: 0-500), ¹⁶ (normal range: 10-200)

N = number, IQR = interquartile range

- = no missing data

*Undernutrition was defined as body mass index < 21; obesity was defined as body mass index ≥ 30

**Cognitive impairment was defined as a score of <24 for the Mini-Mental State Examination (MMSE) test or the presence of cognitive impairment symptoms (wandering, hallucination, hostility/aggressiveness or cognitive disorder history)

***of the 463 residents still alive on 21 March, 2020 (17 patients died between 1 March and 21 March 2020)

**** Neutropenia was defined as a neutrophil level <1.5 G/L; lymphopenia was defined as a lymphocyte level <1.0 G/L, and

thrombocytopenia was defined as a platelet level < 150 G/L

ENT = ear, nose and throat; CRP = C-reactive protein; AST = aspartate aminotransferase; ALT = alanine aminotransferase; AP = alkaline phosphatase; GGT = gamma glutamyl transferase; GFR = glomerular filtration rate; CPK = creatine phosphokinase; RT-PCR = reverse transcriptase-polymerase chain reaction

547 **Table 2.** Variables associated with an increased risk of hospitalization: univariate analysis of 123
 548 hospitalizations in 463 residents
 549

Variables	Total N=463 (%)	Not hospitalized N=340 (%)	Hospitalized N=123 (%)	sHR	CI 95%	p
Gender (male)	318 (68.7)	248 (72.9)	70 (56.9)	1.77	[1.25-2.52]	0.001
Comorbidities						
Cognitive impairment *	391 (84.4)	280 (82.4)	111 (90.2)	1.81	[1.00-3.29]	0.050
Type 2 diabetes	84 (18.1)	48 (14.1)	36 (29.3)	2.03	[1.39-2.95]	<0.0001
Congestive heart failure	70 (15.1)	42 (12.4)	28 (22.8)	1.88	[1.23-2.87]	0.003
Atrial fibrillation	88 (19.0)	57 (16.8)	31 (25.2)	1.55	[1.03-2.32]	0.034
Symptoms	365 (78.8)	252 (74.1)	113 (91.9)	3.38	[1.77-6.43]	<0.0001
Dyspnea	163 (35.2)	96 (28.2)	67 (54.5)	2.51	[1.77-3.57]	<0.0001
Thermal dysregulation	222 (47.9)	147 (43.2)	75 (61.0)	1.83	[1.28-2.62]	0.001
Gastrointestinal symptoms	82 (17.7)	52 (15.3)	30 (24.4)	1.61	[1.07-2.42]	0.021
Altered level of consciousness	32 (10.9)	12 (3.5)	20 (16.3)	3.34	[2.12-5.26]	<0.0001
Biology						
CRP (IQR)	26.0 (7.0-68.0)	18.0 (5.0-56.8)	35.0 (13.0-120.0)	1.01	[1.00-1.01]	<0.0001
High CPK level	21 (4.5)	8 (2.4)	13 (10.6)	1.98	[1.00-3.88]	0.050
AST (IQR)	25.0 (20.0-36.0)	22.0 (18.0-29.0)	30.0 (23.0-55.8)	1.03	[1.02-1.03]	<0.0001
Treatment						
Antibiotics (except azithromycin)	329 (71.1)	227 (66.8)	102 (82.9)	2.09	[1.30-3.37]	0.002
Hydration	210 (45.4)	140 (11.8)	70 (56.9)	1.67	[1.17-2.38]	0.004
Oxygen therapy	153 (33.0)	83 (24.4)	70 (56.9)	3.13	[2.20-4.46]	<0.0001
Aerosol	11 (2.4)	5 (1.5)	6 (4.9)	2.03	[1.07-3.83]	0.029
Contraindications	46 (9.9)	27 (7.9)	19 (15.4)	1.81	[1.12-2.92]	0.014

550 sHR = specific hazard ratio
 551 *Cognitive impairment was defined as a score < 24 according to the Mini-Mental State Examination (MMSE) test, or the presence of
 552 cognitive impairment symptoms (wandering, hallucination, hostility/aggressiveness or cognitive disorder history)
 553 N = number, IQR = interquartile range
 554 High CPK level was defined as CPK > 200 UI/L
 555 CRP = C-reactive protein; AST = aspartate aminotransferase; CPK = creatine phosphokinase
 556
 557
 558
 559
 560
 561
 562
 563
 564
 565
 566
 567
 568
 569

570 **Table 3.** Variables associated with an increased risk of mortality: univariate analysis of 96 deaths in
 571 480 residents
 572

Variables	Total N=480 (%)	Survived N=384 (%)	Deceased N=96 (%)	OR	CI 95%	p
Age > 85 years	301 (62.7)	228 (59.4)	73 (76.0)	2.17	[1.30-3.62]	0.003
Gender (male)	145 (31.3)	92 (27.1)	53 (43.1)	2.04	[1.33-3.14]	0.001
Polymedication ≥ 5 drugs for pre- existing comorbidities	348 (72.5)	291(75.8)	57 (59.4)	0.47	[0.29-0.75]	0.001
Comorbidities						
Dyslipidemia	31 (6.5)	19 (4.9)	12 (12.5)	2.74	[1.28-5.87]	0.009
Atrial fibrillation	91 (19.0)	66 (17.2)	25 (26.0)	1.70	[1.00-2.88]	0.049
Psychiatric disorders	51 (10.6)	47 (12.2)	4 (4.2)	0.31	[0.11-0.89]	0.029
Chronic kidney disease	69 (14.4)	48 (12.5)	21 (21.9)	1.96	[1.11-3.47]	0.021
Symptoms	371 (77.3)	280 (72.7)	91 (95.8)	15.89	[3.84-65.68]	<0.0001
Dyspnea	171 (35.6)	110 (28.4)	62 (64.6)	4.60	[2.87-7.9]	<0.0001
Thermal dysregulation	231 (48.1)	167 (43.5)	64 (66.7)	2.6	[1.62-4.16]	<0.0001
Falls	39 (8.1)	26 (6.8)	13 (13.5)	2.16	[1.06-4.38]	0.033
Altered level of consciousness	32 (6.7)	20 (5.2)	12 (12.5)	2.60	[1.22-5.53]	0.013
Biology						
GFR (IQR)	41.1 (29.8-57.5)	43.2 (32.2-58.9)	32.0 (17.5-49.3)	0.98	[0.97-0.99]	0.004
CRP (IQR)	26.0 (7.0-67.0)	18 (5.0-53.3)	80 (31.0-150.0)	1.02	[1.01-1.02]	<0.0001
High CPK level	22 (26.8)	8 (14.8)	14 (50.0)	5.75	[2.00-16.51]	0.001
AST (IQR)	25.0 (20.0-36.0)	23.0 (18.5-32.0)	35.0 (24.0-60.0)	1.03	[1.01-1.05]	0.002
Treatment						
Azithromycin	375 (78.1)	308 (80.2)	67 (69.8)	0.57	[0.35-0.94]	0.028
Hydration	220 (45.8)	154 (40.1)	66 (68.8)	3.29	[2.04-5.30]	<0.0001
Preventive anticoagulation	203 (42.3)	175 (45.6)	28 (29.2)	0.49	[0.30-0.80]	0.004
Oxygen therapy	163 (34.0)	94 (24.5)	69 (71.9)	7.88	[4.77-13.03]	<0.0001
Hospitalization	128 (26.7)	84 (21.9)	44 (45.8)	3.02	[1.89-4.83]	<0.0001

573

574 OR = odds ratio

575 N = number, IQR = interquartile range


576 High CPK level was defined as CPK > 200 UI/

577 CRP = C-reactive protein; AST = aspartate aminotransferase; GFR = glomerular filtration rate

578

579

Multivariate analysis of factors associated with time to hospitalization with death as competitive risk



Multivariate analysis of factors associated with death

